Primary information |
---|
sequence ID | Seq_2978 |
Peptide sequence | GPPDVPDHAAYHPF |
CancerPDF_ID | CancerPDF_ID47, CancerPDF_ID797, CancerPDF_ID3257, |
PMID | 16896061,19795908,21267442 |
Protein Name | Inter-alpha-trypsin inhibitor heavy chain H5,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4 |
UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
Fluid | Serum,Plasma,Serum |
M/Z | 1519.7,760.34,1520 |
Charge | 1,2,NA |
Mass (in Da) | 1519.69,NA,NA |
fdr | NA,NA,NA |
Profiling Technique | MALDI-TOF,LC-MS,MALDI-TOF |
Peptide Identification technique | Q/TOF MS/MS,MALDI-TOF/TOF,LC-MS-MS/MS |
Quantification Technique | NA,LC-MRM (multiple reaction monitoring),LC-ESI-MS |
Labelled/Label Free | Label Free,Labelled,Label Free |
FDR | NA,less than 7%,NA |
CancerPDF_ID | CancerPDF_ID47, CancerPDF_ID797, CancerPDF_ID3257, |
p-Value | 1.00E-05,NA,NA |
Software | MASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,NA |
Length | 14,14,14 |
Cancer Type | Metastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),Stomach adenocarcinoma |
Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NA |
Modification | NA,NA,NA |
Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 28 patients",41 and 21 patients are in training dataset and testing dataset respectively; 21 and 12 Normal healthy individual s are in training dataset and testing dataset respectively |
Regulation | NA,NA,NA |
Validation | Independent validation,NA,Independent validation |
Sensitivity | 95% on independent dataset,NA,NA |
Specificity | 95% on independent dataset,NA,NA |
Accuracy | NA,NA,NA |
Peptide Atlas | NA |
IEDB | |